Timothy Price
Timothy Price
The Queen Elizabeth Hospital and School of Medicine University of Adelaide
Verified email at
Cited by
Cited by
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ...
New England Journal of Medicine 359 (17), 1757-1765, 2008
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
Cetuximab for the treatment of colorectal cancer
DJ Jonker, CJ O'Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au, ...
New England Journal of Medicine 357 (20), 2040-2048, 2007
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with …
M Peeters, T Jay Price
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
J Tie, Y Wang, C Tomasetti, L Li, S Springer, I Kinde, N Silliman, M Tacey, ...
Science translational medicine 8 (346), 346ra92-346ra92, 2016
The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity
J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ...
Nature 575 (7781), 217-223, 2019
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer
DG Haller, J Tabernero, J Maroun, F De Braud, T Price, E Van Cutsem, ...
J Clin Oncol 29 (11), 1465-1471, 2011
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ...
New England Journal of Medicine 383 (13), 1207-1217, 2020
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced …
P Ross, M Nicolson, D Cunningham, J Valle, M Seymour, P Harper, ...
Journal of clinical oncology 20 (8), 1996-2004, 2002
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III …
NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ...
Journal of clinical oncology 28 (19), 3191-3198, 2010
Management of gastric cancer in Asia: resource-stratified guidelines
L Shen, YS Shan, HM Hu, TJ Price, B Sirohi, KH Yeh, YH Yang, T Sano, ...
The Lancet Oncology 14 (12), e535-e547, 2013
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non …
TJ Price, M Peeters, TW Kim, J Li, S Cascinu, P Ruff, AS Suresh, ...
The Lancet Oncology 15 (6), 569-579, 2014
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients
HJ Schmoll, T Cartwright, J Tabernero, MP Nowacki, A Figer, J Maroun, ...
Journal of Clinical Oncology 25 (1), 102-109, 2006
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
E Van Cutsem, YJ Bang, F Feng-Yi, JM Xu, KW Lee, SC Jiao, JL Chong, ...
Gastric Cancer 18 (3), 476-484, 2015
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, ...
New England Journal of Medicine 384 (25), 2371-2381, 2021
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE …
HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ...
The Lancet Oncology 18 (9), 1159-1171, 2017
Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase …
HJ Schmoll, J Tabernero, J Maroun, F De Braud, T Price, E Van Cutsem, ...
Journal of Clinical Oncology 33 (32), 3733-3740, 2015
Colorectal cancer: Metastases to a single organ
S Vatandoust, TJ Price, CS Karapetis
World journal of gastroenterology 21 (41), 11767, 2015
Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced …
TJ Price, JE Hardingham, CK Lee, A Weickhardt, AR Townsend, JW Wrin, ...
J Clin Oncol 29 (19), 2675-2682, 2011
The system can't perform the operation now. Try again later.
Articles 1–20